Search: WFRF:(Boon Baayla D.C.) >
Amyloid-β PET and C...
Amyloid-β PET and CSF in an autopsy-confirmed cohort
-
- Reimand, Juhan (author)
- North Estonia Medical Centre,Amsterdam UMC - Vrije Universiteit Amsterdam,Tallinn University of Technology,Vrije Universiteit Amsterdam
-
- Boon, Baayla D.C. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
- Collij, Lyduine E. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
show more...
-
- Teunissen, Charlotte E. (author)
- Vrije Universiteit Amsterdam,Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Rozemuller, Annemieke J.M. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
- van Berckel, Bart N.M. (author)
- Vrije Universiteit Amsterdam,Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Scheltens, Philip (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
- Ossenkoppele, Rik (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
- Bouwman, Femke (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
-
show less...
-
(creator_code:org_t)
- 2020-10-20
- 2020
- English 11 s.
-
In: Annals of Clinical and Translational Neurology. - : Wiley. - 2328-9503. ; 7:11, s. 2150-2160
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Objective: Accumulation of amyloid-β is among the earliest changes in Alzheimer’s disease (AD). Amyloid-β positron emission tomography (PET) and Aβ42 in cerebrospinal fluid (CSF) both assess amyloid-β pathology in-vivo, but 10–20% of cases show discordant (CSF+/PET− or CSF-/PET+) results. The neuropathological correspondence with amyloid-β CSF/PET discordance is unknown. Methods: We included 21 patients from our tertiary memory clinic who had undergone both CSF Aβ42 analysis and amyloid-β PET, and had neuropathological data available. Amyloid-β PET and CSF results were compared with neuropathological ABC scores (comprising of Thal (A), Braak (B), and CERAD (C) stage, all ranging from 0 [low] to 3 [high]) and neuropathological diagnosis. Results: Neuropathological diagnosis was AD in 11 (52%) patients. Amyloid-β PET was positive in all A3, C2, and C3 cases and in one of the two A2 cases. CSF Aβ42 was positive in 92% of ≥A2 and 90% of ≥C2 cases. PET and CSF were discordant in three of 21 (14%) cases: CSF+/PET− in a patient with granulomatosis with polyangiitis (A0B0C0), CSF+/PET− in a patient with FTLD-TDP type B (A2B1C1), and CSF-/PET+ in a patient with AD (A3B3C3). Two CSF+/PET+ cases had a non-AD neuropathological diagnosis, that is FTLD-TDP type E (A3B1C1) and adult-onset leukoencephalopathy with axonal spheroids (A1B1C0). Interpretation: Our study demonstrates neuropathological underpinnings of amyloid-β CSF/PET discordance. Furthermore, amyloid-β biomarker positivity on both PET and CSF did not invariably result in an AD diagnosis at autopsy, illustrating the importance of considering relevant comorbidities when evaluating amyloid-β biomarker results.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database